Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
Immunization
Infection
Multiple sclerosis
Prevention
Vaccine
Journal
Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
30
03
2019
revised:
31
03
2019
accepted:
11
04
2019
pubmed:
1
5
2019
medline:
17
1
2020
entrez:
1
5
2019
Statut:
ppublish
Résumé
To establish recommendations on immunization for patients with multiple sclerosis (MS). Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients. The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain. Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs. Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS.
Sections du résumé
OBJECTIVES
OBJECTIVE
To establish recommendations on immunization for patients with multiple sclerosis (MS).
BACKGROUND
BACKGROUND
Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients.
METHODS
METHODS
The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain.
RESULTS
RESULTS
Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs.
CONCLUSION
CONCLUSIONS
Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS.
Identifiants
pubmed: 31036391
pii: S0035-3787(19)30594-6
doi: 10.1016/j.neurol.2019.04.001
pii:
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Practice Guideline
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-357Investigateurs
V Abadie
(V)
C Achour
(C)
F Ader
(F)
H Alchaar
(H)
A Alkhedr
(A)
F Andreux
(F)
G Androdias
(G)
R Arjmand
(R)
B Audoin
(B)
D Audry
(D)
D Aufauvre
(D)
C Autreaux
(C)
X Ayrignac
(X)
M Bailbe
(M)
M Benazet
(M)
C Bensa
(C)
D Bensmail
(D)
E Berger
(E)
P Bernady
(P)
Y Bertagna
(Y)
D Biotti
(D)
A Blanchard-Dauphin
(A)
J Bonenfant
(J)
M Bonnan
(M)
B Bonnemain
(B)
F Borgel
(F)
E Botelho-Nevers
(E)
S Boucly
(S)
B Bourre
(B)
C Boutière
(C)
P Branger
(P)
D Brassat
(D)
S Bresch
(S)
V Breuil
(V)
B Brochet
(B)
H Brugeilles
(H)
P Bugnon
(P)
P Cabre
(P)
J-P Camdessanché
(JP)
C Carra-Dalière
(C)
O Casez
(O)
J-M Chamouard
(JM)
B Chassande
(B)
P Chataignier
(P)
M Chbicheb
(M)
A Chenet
(A)
J Ciron
(J)
P Clavelou
(P)
M Cohen
(M)
R Colamarino
(R)
N Collongues
(N)
I Coman
(I)
P-R Corail
(PR)
S Courtois
(S)
M Coustans
(M)
A Creange
(A)
E Creisson
(E)
N Daluzeau
(N)
C Davenas
(C)
J De Seze
(J)
M Debouverie
(M)
R Depaz
(R)
N Derache
(N)
L Divio
(L)
X Douay
(X)
C Dulau
(C)
F Durand-Dubief
(F)
G Edan
(G)
Z Elias
(Z)
O Fagniez
(O)
M Faucher
(M)
J-M Faucheux
(JM)
M Fournier
(M)
A Gagneux-Brunon
(A)
P Gaida
(P)
P Galli
(P)
P Gallien
(P)
J Gaudelus
(J)
D Gault
(D)
A Gayou
(A)
M Genevray
(M)
A Gentil
(A)
J Gere
(J)
L Gignoux
(L)
M Giroux
(M)
P Givron
(P)
O Gout
(O)
J Grimaud
(J)
A-M Guennoc
(AM)
N Hadhoum
(N)
P Hautecoeur
(P)
O Heinzlef
(O)
M Jaeger
(M)
S Jeannin
(S)
L Kremer
(L)
A Kwiatkowski
(A)
P Labauge
(P)
C Labeyrie
(C)
S Lachaud
(S)
I Laffont
(I)
C Lanctin-Garcia
(C)
J Lannoy
(J)
L Lanotte
(L)
D Laplaud
(D)
D Latombe
(D)
M Lauxerois
(M)
E Le Page
(E)
C Lebrun-Frenay
(C)
P Lejeune
(P)
P Lejoyeux
(P)
B Lemonnier
(B)
E Leray
(E)
C-M Loche
(CM)
C Louapre
(C)
C Lubetzki
(C)
A Maarouf
(A)
B Mada
(B)
L Magy
(L)
E Maillart
(E)
E Manchon
(E)
R Marignier
(R)
P Marque
(P)
G Mathey
(G)
A Maurousset
(A)
C Mekies
(C)
M Merienne
(M)
L Michel
(L)
A-M Milor
(AM)
X Moisset
(X)
A Montcuquet
(A)
T Moreau
(T)
N Morel
(N)
M Moussa
(M)
J-P Naudillon
(JP)
M Normand
(M)
P Olive
(P)
J-C Ouallet
(JC)
O Outteryck
(O)
C Pacault
(C)
C Papeix
(C)
I Patry
(I)
D Peaureaux
(D)
J Pelletier
(J)
B Pichon
(B)
S Pittion
(S)
E Planque
(E)
M-C Pouget
(MC)
V Pourcher
(V)
C Radot
(C)
I Robert
(I)
F Rocher
(F)
A Ruet
(A)
A Ruet
(A)
C Saint-Val
(C)
J-Y Salle
(JY)
A Salmon
(A)
E Sartori
(E)
S Schaeffer
(S)
B Stankhof
(B)
F Taithe
(F)
E Thouvenot
(E)
C Tizon
(C)
A Tourbah
(A)
P Tourniaire
(P)
M Vaillant
(M)
P Vermersch
(P)
S Vidil
(S)
A Wahab
(A)
M-H Warter
(MH)
S Wiertlewski
(S)
B Wiplosz
(B)
B Wittwer
(B)
C Zaenker
(C)
H Zephir
(H)
Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.